Clinicians often prefer levodopa-sparing strategies (e.g. non-ergot dopamine agonists (DAs) or monoamine oxidase B (MAO-B) inhibitors) as initial therapy, especially among younger patients at higher risk of motor fluctuations and dyskinesia. Here, MAOB is linked to Dyskinesia.